I am writing to you regarding a paper entitled 'Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals', which was recently published in Gene Therapy. 1 The authors use a 'recently established cardiac-directed recirculating method of gene delivery' to administer three different doses (low, medium and high) of AAV2/1SERCA2a to sheep with pacing-induced heart failure. The control animals received no vector. Pacing was resumed after gene (or control ¼ no gene) delivery for an additional 4-6 weeks. Echocardiographic and LV pressure measurements were carried out at the termination of the study.
In this largely negative study, the results were presented in a manner making evaluation of the significance of the findings difficult. For example, in the abstract, it is stated that gene therapy 'elicited a dosedependent improvement in cardiac performance determined by left ventricular pressure analysis (+dP/dt max; low dose À220±70, P40.05; medium dose 125±53, Po0.05, high dose 287 ± 104, Po0.05).' Yet, the authors do not provide the absolute values for dP/dt after gene therapy to allow the reader to evaluate the relative magnitude of the final values of dP/dt in each group. Given that there were baseline differences in dP/dt of over 200 mmHg among the groups in some cases (control dP/dt 814 ± 121 mmHg vs high-dose dP/dt 615±98.6 mm Hg, Table 1 ), if one compared absolute values of the actual dP/dt in these groups (rather than the delta values), one would likely find that there was in fact no significant difference in the positive dP/dt between the controls and the high-dose group at the time of killing. Similarly, given that the baseline EF was 37% in the control group and 25% in the high-dose group (Table 1, Figure 2) , showing a positive improvement in EF in the high-dose group, averaging approximately 10%, and a negative change in EF of 4% in the control group, indicates that there was likely no significant difference in the ejection fraction in the high-dose group compared with that in the control group at the end of the study.
In addition to the largely negative results, the authors fail to describe their 'recirculation' method adequately. In an earlier description of this technique, 2 the authors failed to reference either of our papers that had earlier described methods for using cardiac isolation with cardiopulmonary bypass in situ as a method for achieving global vector-mediated, recirculating gene delivery to the heart. 3, 4 As we were the first to create a truly recirculating model of cardiac gene delivery, our work should have been cited. The importance of acknowledging earlier art is particularly important, given that the authors have commercialized their technology and as they apparently hoped to achieve a similar degree of cardiac isolation as we had achieved, using a cardiac surgical approach (molecular cardiac surgery) with their catheter-based methodology. Our contention, supported by the results of this manuscript, is that the authors intended to successfully modify our recirculating model of cardiac gene delivery using a percutaneous approach but that they have not been successful. In fact, quite unlike our methodology, which is at least 97% to 499% efficient in isolating the heart from the systemic circulation (3, unpublished qPCR data), this method ('V-Focus') results in the loss of more than 99% of the vector into the systemic circulation. Furthermore, neither in the original description of their method 2 nor in this manuscript 1 do the authors ever answer several critically important questions about their gene delivery technique: (1) What were the flow rates achieved in your 'closed loop' system? (2) What were the delivery pressures? (3) What was the duration of perfusion? (3) How did you deal with the hemiazygous vein that drains into the coronary sinus in the sheep? (4) Provide anatomical details of how 'the draining catheter was placed in such a position to exclude the azygous vein.' Without belaboring this issue, it is clear that the 'VFocus' method 2 is not at all a 'closed loop' system for a variety of reasons. If the flow through the system (information not provided) were, for example, 20% of the flow rate of normal coronary blood flow, then only 20 % of the vector infused would recirculate on the second pass through the system and only 4% would recirculate on the third pass and 0.8% would recirculate on the fourth pass. Thus, each virus would pass through the coronary circulation an average of o1.3 times or essentially one-pass kinetics, despite the description of this technique as a 'recirculation' method. Furthermore, as all of the blood flow to the heart through the coronary arteries does not return through the coronary sinus, there would be a further reduction in the fraction of vector retrieved from the coronary sinus as all of the vector that returned through the Thebesian veins would be lost into the systemic circulation. Finally, as the authors fail to explain how they deal with the hemiazygous vein that drains into the coronary sinus in the sheep it is likely that nearly all of their vector was lost into the systemic circulation after one pass. Thus, a conservative estimate is that, with this technique, 499% of the vector promptly disappears into the systemic circulation and does not 'recirculate' at all. The authors could have studied this by carrying out qPCR on the 'recirculating' blood to measure the rate of disappearance of the vector, but they did not, or at least they did not report the results.
Gene Therapy (2009) 16, 939-940 The proof of this contention-that 499% of the vector is lost into the systemic circulation using the 'VFocus' method-is provided by the authors themselves. In the high-dose group, they found only an average of 2639 vector genomes per microgram of DNA in the myocardium. Meanwhile, they found an average of 69 595 vector genomes per microgram of DNA in the liver. Thus, the concentration of vector genomes in the liver was 26.4 times higher than that in the heart. As the mass of the average (human) heart is 300 grams and the mass of the average (human) liver is 41.2 kg, assuming similar proportions in the sheep, we can conservatively predict that there was at least 100 times as much vector in the sheep's liver than there was in the sheep's heart. Thus, more than 99% of the vector ended up in the systemic circulation and not in the heart at all. This method is not a recirculation method and should neither be marketed nor represented as such. In our approach, 3, 4 we use cardiopulmonary bypass, and we truly isolate the heart and truly 'recirculate' as we (a) ligate the hemiazygous vein in sheep (dogs and humans do not have one); (b) collect 100% of blood that enters both coronary arteries when using an antegrade approach, as we recover not only from the coronary sinus but also from the left and right ventricular cavities all blood that returns through the Thebesian veins. Similarly, we can use a retrograde delivery approach and recover from the aortic root as well as from the ventricular cavities, including all Thebesian vein flow; 4 and finally, (c) unlike the approach of Byrne et al., 1 we are able to wash essentially all of the vector out of the circulation at the end of the recirculation period. 3, 4 In the 'V-focus' method, virtually 100% of the vector has already been lost into the systemic circulation at the end of the 'recirculation' interval and thus can never be recovered. In summary, the proof that this is not a recirculation method lies in the fact that more than 99% of the vector is in the liver and not in the heart at the conclusion of the 'recirculation' interval. I suspect that very low flows were achieved in this system because of the length and small caliber of the catheters used. In our approach, flows of up to 300 cc min -1 are achieved (similar to normal total coronary blood flow). The authors never provide the critically important information regarding the flow rates in their system. This information is important as, the lower their flow rates, the more rapidly the vector is lost into the systemic circulation using the 'V-Focus' system. Flow rates of 3 cc min -1 would imply 499% loss in the first pass; 6cc min -1 would imply 498% loss, and so on. The percentage loss would be even higher if the hemiazygous vein were not occluded and could approach 100% with the first pass assuming a total coronary artery blood flow rate of 300 cc min -1 . It should be pointed out that the 'V-focus' technique, like ours, uses cardiopulmonary (partial) bypass, but unlike ours, it ignores several important aspects of anatomy and the principles of conservation of mass. In developing this technique, the
